Artesunate (ART), an artemisinin derivative, overcomes sunitinib resistance in renal cancer, with ferroptosis observed specifically in KTCTL-26 cells via ROS burst, metabolic rewiring, and p53 induction, suggesting p53 as a potential biomarker for ART responsiveness (235, 236). Here, TP53 is linked to renal carcinoma.